Anavex Life Sciences (AVXL) Shareholder's Equity Growth (5y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.29% |
| Sep 30, 2025 | 28.35% |
| Jun 30, 2025 | 29.81% |
| Mar 31, 2025 | 32.11% |
| Dec 31, 2024 | 33.70% |
| Sep 30, 2024 | 42.75% |
| Jun 30, 2024 | 43.69% |
| Mar 31, 2024 | 51.01% |
| Dec 31, 2023 | 47.43% |
| Sep 30, 2023 | 44.75% |
| Jun 30, 2023 | 44.14% |
| Mar 31, 2023 | 45.22% |
| Dec 31, 2022 | 39.54% |
| Sep 30, 2022 | 40.65% |
| Jun 30, 2022 | 45.08% |
| Sep 30, 2021 | 88.67% |
| Sep 30, 2020 | 16.29% |
| Jun 30, 2020 | 30.31% |
| Mar 31, 2020 | 39.44% |
| Dec 31, 2019 | 122.77% |
| Sep 30, 2019 | 153.81% |
| Jun 30, 2019 | 23.39% |
| Mar 31, 2019 | 15.37% |
| Dec 31, 2018 | 68.67% |
| Sep 30, 2018 | 61.72% |
| Jun 30, 2018 | 53.91% |
| Mar 31, 2018 | 53.58% |
| Dec 31, 2017 | 57.44% |
| Sep 30, 2017 | 61.55% |
| Jun 30, 2017 | 66.17% |
| Sep 30, 2016 | 49.71% |
| Sep 30, 2015 | 44.62% |